Allogene stockholders approve increase in authorized common shares to 800 million

• Allogene Therapeutics held its annual shareholder meeting on June 18, 2026.
• Shareholders backed a charter amendment to raise authorized common shares to 800 million from 400 million; the filing was completed June 18, 2026.
• Investors ratified Ernst & Young as independent auditor for the fiscal year ending Dec. 31, 2026.
• An advisory vote set annual frequency for future say-on-pay votes; the board plans to hold them every year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-044618), on June 22, 2026, and is solely responsible for the information contained therein.